Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharmacol ; 903: 174132, 2021 Jul 15.
Article in English | MEDLINE | ID: mdl-33933466

ABSTRACT

Opioid-induced constipation is the most prevalent adverse effect of opioid drugs. Peripherally acting mu opioid receptor antagonists (PAMORAs), including naloxegol, are indicated for the treatment of opioid-induced constipation. The aim of this study was the in vitro and in vivo pharmacological characterization of naloxegol in comparison with naloxone. In vitro experiments were performed to measure calcium mobilization in cells coexpressing opioid receptors and chimeric G proteins and mu receptor interaction with G protein and ß-arrestin 2 using bioluminescence resonance energy transfer. In vivo experiments were performed in mice to measure pain threshold using the tail withdrawal assay and colonic transit using the bead expulsion assay. In vitro, naloxegol behaved as a selective and competitive mu receptor antagonist similarly to naloxone, being 3-10-fold less potent. In vivo, naloxone was effective in blocking fentanyl actions when given subcutaneously (sc), but not per os (po). In contrast, naloxegol elicited very similar effects with sc or po administration counteracting in a dose dependent manner the constipating effects of fentanyl without interfering with the fentanyl mediated analgesia. Thus, a useful PAMORA action could be obtained with naloxegol both after po and sc administration.


Subject(s)
Constipation/drug therapy , Morphinans/pharmacology , Narcotic Antagonists/pharmacology , Polyethylene Glycols/pharmacology , Administration, Oral , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/adverse effects , Analgesics, Opioid/pharmacology , Animals , Behavior, Animal/drug effects , CHO Cells , Calcium/metabolism , Constipation/chemically induced , Cricetulus , Fentanyl/administration & dosage , Fentanyl/adverse effects , Fentanyl/pharmacology , Injections, Subcutaneous , Male , Mice , Morphinans/administration & dosage , Morphine/pharmacology , Naloxone/administration & dosage , Naloxone/pharmacology , Narcotic Antagonists/administration & dosage , Pain/drug therapy , Polyethylene Glycols/administration & dosage , Receptors, Opioid, mu/antagonists & inhibitors , Receptors, Opioid, mu/drug effects
2.
J Med Chem ; 63(19): 10782-10795, 2020 10 08.
Article in English | MEDLINE | ID: mdl-32901477

ABSTRACT

Nociceptin/orphanin FQ (N/OFQ) controls different biological functions via selective stimulation of the N/OFQ peptide (NOP) receptor. The pleiotropic actions of N/OFQ may limit the development of NOP ligands as innovative drugs in different therapeutic areas. The pharmacological concept of functional selectivity (aka biased agonism) might be useful for amplifying beneficial actions and/or counteracting side effects. Thus, molecules with large bias factors toward G protein or ß arrestin are required for investigating the translational value of NOP biased modulation. Herein, the biased behavior of a heterogeneous library of NOP-targeting peptide derivatives was evaluated in vitro with the aim to provide possible insights into the structural determinants that govern the selective activation of G protein versus ß-arrestin. Our results demonstrate that lipidation of N/OFQ(1-13)-NH2 is a useful strategy for obtaining G protein biased agonists for the NOP receptor.


Subject(s)
Opioid Peptides/pharmacology , Peptide Fragments/agonists , Receptors, Opioid/agonists , Animals , GTP-Binding Proteins/chemistry , Peptide Fragments/chemistry , Receptors, Opioid/chemistry , Structure-Activity Relationship , Nociceptin Receptor , Nociceptin
3.
Bioconjug Chem ; 30(9): 2444-2451, 2019 09 18.
Article in English | MEDLINE | ID: mdl-31461266

ABSTRACT

The general aim of the work was the validation of a new synthetic methodology designed for obtaining bifunctional heterotetrabranched peptide ligands. Applying an easily accessible synthetic route, we provided a small series of heteromultimeric peptide conjugates targeting the nociceptin/orphanin FQ (N/OFQ) peptide receptors (NOP) and mu opioid receptors. Among these, H-PWT1-N/OFQ-[Dmt1]dermorphin demonstrated a similar and high agonist potency at the NOP and mu receptors. The achieved results confirmed the robustness of the approach that is extremely versatile and virtually applicable to different peptide sequences whose pharmacological activity can be combined for generating dual acting multimeric compounds. These innovative pharmacological tools will be extremely helpful for investigating the consequences of the simultaneous activation and/or blockage of different peptidergic receptors.


Subject(s)
Peptides/chemistry , Peptides/pharmacology , Receptors, Opioid, mu/agonists , Receptors, Opioid/agonists , Animals , Benzaldehydes/chemistry , CHO Cells , Cricetulus , Humans , Maleimides/chemistry , Nociceptin Receptor
SELECTION OF CITATIONS
SEARCH DETAIL
...